Buder, Anna
Setinek, Ulrike
Hochmair, Maximilian J.
Schwab, Sophia
Kirchbacher, Klaus
Keck, Andrea
Burghuber, Otto C.
Pirker, Robert
Filipits, Martin
Funding for this research was provided by:
AstraZeneca Austria
Article History
First Online: 27 February 2019
Compliance with Ethical Standards
:
: The study was funded by AstraZeneca. Open access funding provided by Medical University of Vienna.
: Anna Buder has received honoraria from AstraZeneca. Maximilian J. Hochmair has received honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, and Roche and had consulting or advisory roles with Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, and Roche. Klaus Kirchbacher received honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, and Roche. Otto C. Burghuber received honoraria from AstraZeneca, Boehringer Ingelheim, Glaxo Smith Kline, Menarini, Chiesi, Takeda, Roche, and Novartis. Robert Pirker has received honoraria from AstraZeneca, Boehringer Ingelheim, and Clovis. Martin Filipits has received honoraria from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Ratiopharm, and Roche. Ulrike Setinek, Sophia Schwab, and Andrea Keck declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.